Research Summary

Noninvasive Vagal Nerve Stimulation Improves Pain, QoL Over 4 Weeks in Adults With Chronic Migraine

Edited by:
Anthony Calabro, MA

Key Highlights

  • Noninvasive vagal nerve stimulation (nVNS) reduced pain intensity and improved quality of life compared with sham treatment.
  • Patients receiving nVNS experienced fewer severe migraine episodes after 4 weeks of treatment.
  • Pain-related interference decreased in the nVNS group, although the effect size was small.

Migraine remains a high-burden neurologic disorder, and a randomized controlled trial published in Physiological Reports evaluated whether noninvasive vagal nerve stimulation (nVNS) improves outcomes in adults with chronic migraine. Over 4 weeks, nVNS significantly reduced pain intensity, frequency, and migraine-related disability while improving quality of life compared with sham treatment.

The trial enrolled 128 adults with chronic migraine, defined by the International Classification of Headache Disorders criteria. Participants were randomized to receive either auricular nVNS or sham stimulation in addition to prescribed medications. The intervention consisted of supervised stimulation sessions using a transcutaneous device applied to the tragus, while the control group received physiologically inactive stimulation at the earlobe. Outcomes were assessed using structured headache diaries, the Numeric Pain Scale (NPS), the Multidimensional Pain Inventory (MPI), and the Migraine-Specific Quality of Life (MS-QoL) questionnaires at baseline and after 4 weeks.

Study Findings

At 4 weeks, the nVNS group demonstrated significantly improved MS-QoL scores compared with controls (mean rank, 94.59 vs 34.41; P < .001), indicating enhanced functional outcomes. Pain intensity, measured by NPS, was also significantly lower in the nVNS group (mean rank, 36.77 vs 92.23; P < .001), with large effect sizes reported for both outcomes.

Headache diary data showed a reduction in severe migraine episodes in the nVNS group, with severe cases decreasing to 20.3% and mild cases increasing to 50% after treatment. In contrast, the control group experienced an increase in severe episodes. Pain-related interference, measured by MPI, showed a statistically significant reduction (P = .035), although the effect size was small, suggesting limited clinical magnitude.

Within-group analyses further supported these findings, with significant improvements in both pain and quality of life observed only in the nVNS group (P <.001), whereas the control group showed no meaningful change.

Clinical Implications

According to the study authors, these findings suggest that nVNS may provide clinically meaningful short-term improvements in pain and quality of life in patients with chronic migraine when used as an adjunct to standard therapy. The authors noted that the intervention demonstrated consistent benefits across multiple patient-reported outcomes.

Key limitations include the single-center design, reliance on subjective patient-reported measures, and short follow-up duration, which limit assessment of long-term efficacy. The absence of objective physiological measures also precludes mechanistic conclusions.

Expert Commentary

“nVNS demonstrated promising clinical benefits in the management of chronic migraine, including reduction in pain intensity, pain-related interventions and behaviors, and improvements in quality of life,” the researchers concluded. “Participants receiving nVNS also showed reduced reliance on pharmacological treatment. However, in the absence of physiological measures confirming autonomic modulation, the underlying mechanisms remain uncertain.”

Reference
Nasir R, Baig MO, Abualait T, et al. Effects of vagal nerve stimulation on pain frequency and intensity in chronic migraine in adults: A randomized controlled trial. Physiol Rep. 2026;doi:10.14814/phy2.70843.